Safety and Efficacy of TGF-beta1/COX-2 Silencing Therapeutic in Adults With Cutaneous Squamous Cell Carcinoma In Situ.
Nestor M, Berman B, Lu P, Molyneaux M.
J Drugs Dermatol. 2022 May 1;21(5):472-477. doi: 10.36849/JDD.6384.
PMID:35533033
Treatment of Cutaneous Squamous Cell Carcinoma In Situ With Curettage Followed by Topical Imiquimod 5% Cream.
Ondo AL, Kerner JD, Kerner JV, Ondo IP, Trainor P, Shanler SD.
Dermatol Surg. 2021 May 1;47(5):609-612. doi: 10.1097/DSS.0000000000002945.
PMID:33905391
Clinical Risk Factors for Cutaneous Squamous Cell Carcinoma in Patients with Actinic Keratosis or Cutaneous Squamous Cell Carcinoma in Situ: A Retrospective Double-cohort Study.
Knuutila JS, Kaijala O, Lehto S, Vahlberg T, Nissinen L, Kähäri VM, Riihilä P.
Acta Derm Venereol. 2024 Nov 27;104:adv40990. doi: 10.2340/actadv.v104.40990.